medi5752
mAbexperimentalMulti-specific
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 24, 2018 (NCT03530397)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05821231 | Phase 1 | Dec 12, 2023 | AstraZeneca, National Cancer Institute, France, University of Toulouse |
| NCT05888857 | Phase 2 | Sep 30, 2023 | AstraZeneca, Institut Bergonié, National Cancer Institute, France |
| NCT05775159 | Phase 2 | Apr 24, 2023 | AstraZeneca |
| NCT05685472 | Phase 1 | Dec 8, 2022 | AstraZeneca |
| NCT04522323 | Phase 1 | Aug 5, 2020 | AstraZeneca, MedImmune |
| NCT03530397 | Phase 1 | Apr 24, 2018 | AstraZeneca, MedImmune |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 2 | 2 | 2018 |
| MedImmune | For profit | 2 | 2 | 1 | 2018 |
| National Cancer Institute, France | Government | 2 | 0 | 2 | 2023 |
| Institut Bergonié | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Toulouse | Academic/Hospital | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1